MOUNTAIN VIEW, Calif., May 29, 2026
NeuroPace, Inc., a leading medical technology company focused on transforming the treatment of drug-resistant epilepsy, has announced U.S. Food and Drug Administration (FDA) approval of ECoG Assistant™, the company’s first artificial intelligence-driven clinician-enabled feature designed to improve epilepsy monitoring and treatment decision-making. The approval marks a significant milestone in the evolution of AI-powered neurological care, enabling physicians to access deeper insights from intracranial electroencephalography (iEEG) data collected through the NeuroPace RNS® System, the world’s first and only commercially available brain-responsive neurostimulation platform for epilepsy. The regulatory clearance represents the first step in NeuroPace’s broader artificial intelligence strategy aimed at improving clinical efficiency, personalizing treatment approaches, and enhancing outcomes for patients living with drug-resistant epilepsy.
AI-Powered ECoG Assistant Enhances Clinical Decision Making
The newly approved ECoG Assistant™ leverages one of the world’s largest and most comprehensive long-term intracranial EEG datasets to assist clinicians in reviewing and interpreting complex neurological data. Developed using more than 124,450 epileptologist-labeled intracranial EEG long-episode records, the AI model is capable of identifying clinically meaningful Electrocorticograms of Interest (ECoGs) and presenting them through advanced visualization tools that streamline patient evaluation. The system enables physicians to review months of neurological activity through a single interface using the ECoG Assistant Trends Report while simultaneously analyzing seizure timing patterns and potential triggers through an integrated Circadian Pattern Chart.
By automating portions of the traditionally time-intensive review process, the technology helps clinicians identify important treatment trends more efficiently, supporting faster and more informed therapeutic decisions. The approval highlights the increasing role of artificial intelligence in neurological disease management and demonstrates how advanced analytics can be integrated into routine clinical workflows to support patient care.
Harnessing the World’s Largest Intracranial EEG Dataset
Advertisement
A key differentiator of NeuroPace’s AI platform is its access to a uniquely extensive repository of patient-specific brain activity data. The ECoG Assistant was trained using proprietary datasets generated through years of clinical use of the RNS System, which continuously records brain activity while delivering personalized neurostimulation therapy at the seizure source. This long-term dataset provides an unprecedented foundation for machine learning applications in epilepsy care. According to NeuroPace, the platform is designed to transform raw neurological data into actionable clinical insights, helping physicians recognize seizure patterns, monitor treatment responses, and optimize therapy settings.
Company executives noted that the FDA approval validates the organization’s strategy of leveraging data-driven innovation to improve healthcare delivery and demonstrates the growing importance of AI-enabled technologies in precision medicine. The approval also positions NeuroPace among a small group of medical technology companies successfully integrating advanced artificial intelligence capabilities into FDA-cleared neurological care solutions.
Building the Future of Personalized Epilepsy Management
The approval of ECoG Assistant represents only the first stage of NeuroPace’s broader vision for AI-enhanced epilepsy management. The company has also submitted its next-generation cloud-based Patient Data Management System (PDMS) for FDA review, which is expected to provide a scalable digital infrastructure capable of supporting future AI-powered applications. If approved, the upgraded platform will improve reliability, streamline clinical workflows, and create opportunities for additional decision-support tools designed to further personalize epilepsy treatment.
NeuroPace plans to officially showcase ECoG Assistant at the American Society for Stereotactic and Functional Neurosurgery (ASSFN) Annual Meeting, where clinicians will gain firsthand experience with the technology. As healthcare systems increasingly adopt artificial intelligence to improve efficiency and patient outcomes, NeuroPace’s latest innovation underscores the growing convergence of neuroscience, digital health, and machine learning. The FDA approval marks a significant advancement in epilepsy care and reinforces the potential of AI-driven medical technologies to transform the future of neurological disease management.
Source: NeuroPace press release
